Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLlorens Cebriá, Carmen
dc.contributor.authorMolina Van den Bosch, Mireia
dc.contributor.authorVergara Arana, Ander
dc.contributor.authorJacobs Cachá, Concepció
dc.contributor.authorSoler Romeo, Maria Jose
dc.date.accessioned2022-08-18T06:31:35Z
dc.date.available2022-08-18T06:31:35Z
dc.date.issued2022-01-16
dc.identifier.citationLlorens-Cebrià C, Molina-Van den Bosch M, Vergara A, Jacobs-Cachá C, Soler MJ. Antioxidant Roles of SGLT2 Inhibitors in the Kidney. Biomolecules. 2022 Jan 16;12(1):143.
dc.identifier.issn2218-273X
dc.identifier.urihttp://hdl.handle.net/11351/8008
dc.descriptionDiabetic kidney disease; Mitochondrial dysfunction; Oxidative stress
dc.description.abstractThe reduction-oxidation (redox) system consists of the coupling and coordination of various electron gradients that are generated thanks to serial reduction-oxidation enzymatic reactions. These reactions happen in every cell and produce radical oxidants that can be mainly classified into reactive oxygen species (ROS) and reactive nitrogen species (RNS). ROS and RNS modulate cell-signaling pathways and cellular processes fundamental to normal cell function. However, overproduction of oxidative species can lead to oxidative stress (OS) that is pathological. Oxidative stress is a main contributor to diabetic kidney disease (DKD) onset. In the kidney, the proximal tubular cells require a high energy supply to reabsorb proteins, metabolites, ions, and water. In a diabetic milieu, glucose-induced toxicity promotes oxidative stress and mitochondrial dysfunction, impairing tubular function. Increased glucose level in urine and ROS enhance the activity of sodium/glucose co-transporter type 2 (SGLT2), which in turn exacerbates OS. SGLT2 inhibitors have demonstrated clear cardiovascular benefits in DKD which may be in part ascribed to the generation of a beneficial equilibrium between oxidant and antioxidant mechanisms.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesBiomolecules;12(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAntioxidants
dc.subjectNefrologia pediàtrica
dc.subject.meshDiabetic Nephropathies
dc.subject.meshAntioxidants
dc.titleAntioxidant Roles of SGLT2 Inhibitors in the Kidney
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/biom12010143
dc.subject.decsnefropatías diabéticas
dc.subject.decsantioxidantes
dc.relation.publishversionhttps://doi.org/10.3390/biom12010143
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Llorens-Cebrià C, Molina-Van den Bosch M] Grup de Recerca en Nefrologia i Trasplantament, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Instituto de Salud Carlos III, Madrid, Spain. [Vergara A, Jacobs-Cachá C, Soler MJ] Grup de Recerca en Nefrologia i Trasplantament, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Instituto de Salud Carlos III, Madrid, Spain
dc.identifier.pmid35053290
dc.identifier.wos000758579800001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/RD21%2F0005%2F0016
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record